Mylan has launched one of the first generic version of Merck’s Cancidas in the US with the launch of Caspofungin Acetate for Injection.
Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this antifungal which has multiple indications.
For the twelve months ending July 31 2017, Caspofungin Acetate for Injection had US sales of approximately $24 million/
Currently, Mylan has 228 ANDAs pending FDA approval, representing approximately $100 billion in annual brand sales.
Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $45.5 billion in annual brand sales.
Caspofungin Acetate for Injection is an echinocandin antifungal indicated in adults and paediatric patients for empirical therapy for presumed fungal infections; treatment of candidemia and the following Candida infections; treatment of esophageal candidiasis, and treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.